Shi & Clark 2025 — Pan IgG Fc receptor blockade reverses chronic pain in IgG-mediated injury
One-paragraph summary
Mouse-model mechanistic and pharmacological study testing whether chronic pain after intervertebral-disc (IVD) injury is causally driven by IgG Fc-receptor signalling, and whether a pan IgG Fc-receptor-interacting molecule (PRIM) reverses the established pain phenotype. After IVD puncture, wild-type mice develop chronic mechanical allodynia and pinch hyperalgesia. At 10 weeks post-injury, expression of excitatory FcγRI and FcγRIII and inhibitory FcγRIIb is elevated in lumbar sensory ganglia and lumbar spinal cord; IgG accumulation is documented in the injured tissues and corresponding spinal cord. Two genetic controls confirm the IgG-axis dependency: (a) Fcγ-chain-knockout mice (which fail to express excitatory IgG Fc receptors) and (b) muMT mice (which cannot produce mature B lymphocytes or antigen-specific IgG) both fail to develop the chronic-pain phenotype. PRIM treatment of disc-injured wild-type mice reverses the established mechanical allodynia and pinch hyperalgesia. For the project's H1 chain, this is a fourth converging line of antibody-removal evidence alongside daratumumab (Fluge & Mella 2025), plasmapheresis+IVIG (Oesch-Régeni 2025), and rituximab (Martín-Martínez 2025). PRIM operates upstream of plasma-cell depletion by blocking the Fc-receptor-mediated effector arm — a therapeutic window distinct from the existing project arms. FcRn blockers are clinically available (efgartigimod, rozanolixizumab) for myasthenia gravis since 2021/2023, suggesting an investigator-initiated stratified trial in autoantibody-positive FM is feasible without IND.
Claims as triples
IgG_fm — present_in → dorsal_root_ganglion[evidence: IgG deposition in lumbar sensory ganglia post IVD injury; confidence: emerging]IgG_fm — causes → widespread_pain[evidence: muMT (B-cell-deficient) mice fail to develop chronic pain; confidence: established (mouse model)]IgG_fm — modulates → small_nerve_fibers[evidence: Fcγ-chain knockout fails to develop chronic pain; confidence: emerging]IgG_fc_receptor_blockade — modulates → widespread_pain[evidence: PRIM reverses established mechanical allodynia + pinch hyperalgesia; confidence: emerging]IgG_fc_receptor_blockade — bridges → fm_autoimmune[evidence: FcRn-blocker class clinically available, candidate for stratified FM trial; confidence: bridging]
Methods note
In vivo mouse model. Strains: wild-type C57BL/6 male mice; Fcγ-chain-knockout (lacking excitatory IgG Fc receptors); muMT (B-cell-deficient, cannot produce IgG). Multi-level lumbar IVD puncture model of low back pain. Nociceptive testing: hindpaw mechanical allodynia (von Frey), pinch hyperalgesia. Molecular characterization: qPCR for FcgrI / FcgrIIb / FcgrIII expression in lumbar sensory ganglia and spinal cord at 10 weeks post-injury; immunoblotting for IgG accumulation in injured tissues. Pharmacological intervention: pan IgG Fc receptor interacting molecule (PRIM) administered post-injury to test for reversal of established pain phenotype. Sample sizes per group not yet verified against the full paper.
Limitations
- Mouse IVD-injury model translates to human chronic low-back pain by analogy, not to FM specifically. The H1 chain in FM operates through anti-SGC IgG with multi-ganglia targets; the IVD-injury model uses local injury with consequent local IgG deposition. The two share the Fc-receptor effector arm but differ in upstream antigen.
- PRIM is a research compound, not a clinical agent. Translation requires either PRIM-class clinical development or substitution with already-approved FcRn blockers (efgartigimod / rozanolixizumab). FcRn blockade is mechanism-equivalent for IgG-half-life reduction but operates via a different arm of IgG biology.
- No FM cohort data. Whether IgG Fc receptor expression is elevated in FM-DRG sections, or whether PRIM-class therapy attenuates FM pain, is open.
Open questions raised
- Are FcγR I/II/III expressed at elevated levels in DRG sections from anti-SGC IgG-positive FM patients? Tractable in stored autopsy tissue if available.
- Does FcRn blockade with efgartigimod or rozanolixizumab attenuate pain in autoantibody-positive FM patients? Clinical-stage agents available; investigator-initiated stratified pilot feasible.
- Is the PRIM mechanism redundant with daratumumab (which depletes the IgG-producing plasma cells upstream), or are they additive? Combined therapy could be more potent in severe autoantibody-driven FM.
Triangulation notes
- Fourth converging line of antibody-removal evidence in chronic pain. Joins daratumumab pilot (plasma-cell depletion, Fluge & Mella 2025), plasmapheresis+IVIG (titer reduction, Oesch-Régeni 2025), and rituximab in HERV-altered ME+MS (B-cell depletion, Martín-Martínez 2025). PRIM blocks the Fc-receptor effector arm rather than reducing the IgG itself — a fourth distinct therapeutic-mechanism window.
- Reinforces the H1 chain causal arrow: IgG → widespread pain. The muMT and Fcγ-chain-knockout controls establish causal necessity in a controlled-genetics system, complementing Goebel 2021's passive-transfer demonstration of causal sufficiency in human-IgG → mouse-pain.
- Adds a new cure-path arm. The white paper §6.1 (BASIS-FM stage 3) currently has daratumumab as the preferred agent. PRIM-class or FcRn-blocker therapy becomes a candidate stage-2.5 or alternative-stage-3 intervention for patients who don't respond to plasma-cell depletion or who cannot tolerate it.
- Compatible with the HERV-mito-loop framework. If HERV-W ENV reactivation drives anti-SGC IgG production (the project's working hypothesis), and PRIM-class therapy interrupts the IgG-effector arm, then PRIM complements temelimab (upstream HERV interrupt) by addressing the residual already-produced autoantibodies.
Bridges
- Strengthens B3 (CRPS ↔ FM via pathogenic IgG) by extending the IgG-mediated chronic-pain framework with a new pharmacological-intervention class.
- New candidate B15 — autoantibody-driven chronic pain ↔ FcRn / Fc-receptor blockade therapy class (efgartigimod, rozanolixizumab, PRIM-class compounds). Drug-class-defined bridge spanning autoantibody-mediated chronic pain conditions.